Limits...
Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.

Matsuda Y, Yoshimura H, Suzuki T, Uchida E, Naito Z, Ishiwata T - Cancer Sci. (2014)

Bottom Line: In this study, we analyzed the expression and roles of total FGFR-2 (both isoforms) to determine the effectiveness of FGFR-2-targeting therapy for PDAC.In response to FGF-2, FGFR-2-shRNA-transfected cells showed decreased phosphorylation of ERK compared with control cells.These findings suggest that FGFR-2 is a therapeutic target for inhibition in PDAC.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Fibroblast growth factor receptor (FGFR)-2-shRNA stably transfected PANC-1 pancreatic ductal adenocarcinoma cells formed smaller s.c. tumors than those in sham cells in nude mice. (a) Graphical representation of tumor volume in nude mice derived from PANC-1 cells. (*P < 0.05 vs Sc4 and Sc-5). (b) Characteristic s.c. tumors in nude mice. Stained with H&E. Bar, upper panel = 1 mm; lower panel = 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4462390&req=5

fig07: Fibroblast growth factor receptor (FGFR)-2-shRNA stably transfected PANC-1 pancreatic ductal adenocarcinoma cells formed smaller s.c. tumors than those in sham cells in nude mice. (a) Graphical representation of tumor volume in nude mice derived from PANC-1 cells. (*P < 0.05 vs Sc4 and Sc-5). (b) Characteristic s.c. tumors in nude mice. Stained with H&E. Bar, upper panel = 1 mm; lower panel = 100 μm.

Mentions: To determine whether FGFR-2 modulated the in vivo proliferation of PDAC cells, FGFR-2-shRNA-transfected PANC-1 cells or sham cells were s.c. injected into nude mice. The FGFR-2-shRNA-transfected cells formed significantly smaller tumors than two different sham cell lines in nude mice (P < 0.05; Fig.7a), but there were no characteristic histological changes in the cells (Fig.7b).


Inhibition of fibroblast growth factor receptor 2 attenuates proliferation and invasion of pancreatic cancer.

Matsuda Y, Yoshimura H, Suzuki T, Uchida E, Naito Z, Ishiwata T - Cancer Sci. (2014)

Fibroblast growth factor receptor (FGFR)-2-shRNA stably transfected PANC-1 pancreatic ductal adenocarcinoma cells formed smaller s.c. tumors than those in sham cells in nude mice. (a) Graphical representation of tumor volume in nude mice derived from PANC-1 cells. (*P < 0.05 vs Sc4 and Sc-5). (b) Characteristic s.c. tumors in nude mice. Stained with H&E. Bar, upper panel = 1 mm; lower panel = 100 μm.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4462390&req=5

fig07: Fibroblast growth factor receptor (FGFR)-2-shRNA stably transfected PANC-1 pancreatic ductal adenocarcinoma cells formed smaller s.c. tumors than those in sham cells in nude mice. (a) Graphical representation of tumor volume in nude mice derived from PANC-1 cells. (*P < 0.05 vs Sc4 and Sc-5). (b) Characteristic s.c. tumors in nude mice. Stained with H&E. Bar, upper panel = 1 mm; lower panel = 100 μm.
Mentions: To determine whether FGFR-2 modulated the in vivo proliferation of PDAC cells, FGFR-2-shRNA-transfected PANC-1 cells or sham cells were s.c. injected into nude mice. The FGFR-2-shRNA-transfected cells formed significantly smaller tumors than two different sham cell lines in nude mice (P < 0.05; Fig.7a), but there were no characteristic histological changes in the cells (Fig.7b).

Bottom Line: In this study, we analyzed the expression and roles of total FGFR-2 (both isoforms) to determine the effectiveness of FGFR-2-targeting therapy for PDAC.In response to FGF-2, FGFR-2-shRNA-transfected cells showed decreased phosphorylation of ERK compared with control cells.These findings suggest that FGFR-2 is a therapeutic target for inhibition in PDAC.

View Article: PubMed Central - PubMed

Affiliation: Departments of Pathology and Integrative Oncological Pathology, Nippon Medical School, Tokyo, Japan; Department of Pathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus